America and Britain Agree to Duty-Free Deal on Medicines.
Britain and America have announced a major trade agreement that will ensure zero duties on UK medicine products going into the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to boost spending on drugs through the National Health Service (NHS). This pledge ensures that tariffs on these crucial products will be held at zero for a period of 36 months.
This deal comes after earlier warnings to significantly raise tariffs on patented pharmaceutical products, with figures floated up to 100%.
"This agreement with the Britain bolsters the international landscape for innovative medicines and brings long-overdue fairness to U.S.–U.K. medicine commerce," an announcement said.
Economic Impact
Drugs constitute one of the UK's largest export categories to the US, which is easily the primary buyer for major British pharmaceutical firms.
Export figures indicate that in the 12 months prior to last September, the UK sold medicines totaling billions to the US. This value represented nearly one-fifth of British export trade in that timeframe.
"This guarantee safeguards employment, boosts investment and sets the stage for the UK to establish itself as a global hub for medical research," the Business and Trade Secretary remarked.
Specific UK Commitments
The agreement includes several notable changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a target to increase total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to control costs will be capped at 15%. In the past, refunds exceeded 20%.
Industry Background
The deal follows a long-running dispute between the pharmaceutical industry and the ministers over drug pricing and approval rates.
The disagreement were exacerbated by claims that US patients were charged significantly more for the same drugs than consumers in the Britain and the EU.
Recently, several large drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had declined as a proportion of its resources over the previous ten-year period.
